Adagene Inc. (ADAG)
NASDAQ: ADAG · IEX Real-Time Price · USD
2.550
+0.110 (4.51%)
At close: May 17, 2024, 3:59 PM
2.820
+0.270 (10.59%)
After-hours: May 17, 2024, 6:11 PM EDT
Adagene Revenue
In the year 2023, Adagene had annual revenue of $18.11M with 94.90% growth.
Revenue (ttm)
$18.11M
Revenue Growth
+94.90%
P/S Ratio
6.04
Revenue / Employee
$104,089
Employees
174
Market Cap
109.41M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 111, Inc. | 2.11B |
| Aurora Cannabis | 200.73M |
| MSP Recovery | 9.71M |
| BeyondSpring | 1.75M |
| Zentek | 25.27K |
ADAG News
- 7 weeks ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewsWire
- 2 months ago - Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire
- 3 months ago - Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 4 months ago - Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 4 months ago - Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium - GlobeNewsWire
- 7 months ago - Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 - GlobeNewsWire
- 7 months ago - Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - GlobeNewsWire